Helmholtz Innovation Labs: HySPRINT at HZB

HZB will be setting up the new Helmholtz HySPRINT Innovation Lab for jointly developing new combinations of materials and processes in energy applications with commercial partners. Silicon and metal-organic perovskite crystals will be the centre point of the Lab’s work. The Helmholtz Association is supporting the project for the next five years with 1.9 million Euros from its Initiative and Networking Fund, with additional contributions from HZB itself as well as from industry.

The Helmholtz Association is supporting a total of seven Helmholtz Innovation Labs in order to strengthen the transfer of research results to the applications domain. The Association is making about twelve million Euros available over the next five years for setting up and operating the Innovation Labs.

The HZB proposal was selected from a field of 27 competing applications. HySPRINT stands for “Hybrid Silicon Perovskite Research, Integration & Novel Technologies”. It will focus on hybrid materials and components based on silicon and perovskite crystals able to be employed for energy conversion in photovoltaics as well as for solar hydrogen production.

“We intend to further develop silicon hybrid technology, liquid-phase crystallisation of silicon, nano-print lithography as well as the implementation of prototypes by means of 3D techniques for microcontacts in cooperation with industrial partners – and demonstrate the potential for industrial-scale production”, says Professor Bernd Rech from the HZB Institute for Silicon Photovoltaics.

The Innovation Lab will be set up as a core lab at HZB and will work closely with the HZB Institute PVcomB. Professor Anke Kaysser-Pyzalla, Scientific Director of HZB poitbs out: “HySPRINT will establish itself as a creative pillar of Technology Transfer at HZB and within the Helmholtz Association.”

red.

  • Copy link

You might also be interested in

  • Green hydrogen: MXenes shows talent as catalyst for oxygen evolution
    Science Highlight
    09.09.2024
    Green hydrogen: MXenes shows talent as catalyst for oxygen evolution
    The MXene class of materials has many talents. An international team led by HZB chemist Michelle Browne has now demonstrated that MXenes, properly functionalised, are excellent catalysts for the oxygen evolution reaction in electrolytic water splitting. They are more stable and efficient than the best metal oxide catalysts currently available. The team is now extensively characterising these MXene catalysts for water splitting at the Berlin X-ray source BESSY II and Soleil Synchrotron in France.
  • SpinMagIC: 'EPR on a chip' ensures quality of olive oil and beer
    News
    04.09.2024
    SpinMagIC: 'EPR on a chip' ensures quality of olive oil and beer
    The first sign of spoilage in many food products is the formation of free radicals, which reduces the shelf-life and the overall quality of the food. Until now, the detection of these molecules has been very costly for the food companies. Researchers at HZB and the University of Stuttgart have developed a portable, small and inexpensive 'EPR on a chip' sensor that can detect free radicals even at very low concentrations. They are now working to set up a spin-off company, supported by the EXIST research transfer programme of the German Federal Ministry of Economics and Climate Protection. The EPRoC sensor will initially be used in the production of olive oil and beer to ensure the quality of these products.
  • Review on ocular particle therapy (OPT) by international experts
    Science Highlight
    03.09.2024
    Review on ocular particle therapy (OPT) by international experts
    A team of leading experts in medical physics, physics and radiotherapy, including HZB physicist Prof. Andrea Denker and Charité medical physicist Dr Jens Heufelder, has published a review article on ocular particle therapy. The article appeared in the Red Journal, one of the most prestigious journals in the field. It outlines the special features of this form of eye therapy, explains the state of the art and current research priorities, provides recommendations for the delivery of radiotherapy and gives an outlook on future developments.